OTCMKTS:MATN Mateon Therapeutics (MATN) Stock Price, News & Analysis $0.06 +0.00 (+8.11%) As of 05/15/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Mateon Therapeutics Stock (OTCMKTS:MATN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mateon Therapeutics alerts:Sign Up Key Stats Today's Range$0.05▼$0.0650-Day Range$0.03▼$0.0552-Week Range$0.13▼$0.38Volume293,464 shsAverage Volume338,444 shsMarket Capitalization$5.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Mateon Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision oncology therapies that selectively target tumor tissue. The company’s platform leverages tumor-activated peptides designed to bind to the fibrin–fibronectin complexes uniquely present in solid tumors, with the goal of improving the therapeutic index of cytotoxic payloads while limiting off-target effects. Its lead asset, MH1, is a peptide–drug conjugate in Phase I clinical trials for advanced solid tumors. MH1 is engineered to remain inert in circulation and to be activated by tumor-associated proteases, delivering potent chemotherapeutic agents directly to the tumor microenvironment. Mateon also maintains a preclinical pipeline exploring additional peptide constructs intended to address cancers with high unmet medical need, such as ovarian and colorectal indications. Headquartered in Redwood City, California, Mateon collaborates with academic research centers and contract development organizations to advance its candidates through IND-enabling studies and early-stage clinical work. The company’s leadership team combines experience in oncology drug development, peptide chemistry and clinical operations, positioning Mateon to progress its targeted therapies toward regulatory milestones and potential strategic partnerships.AI Generated. May Contain Errors. Read More Receive MATN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mateon Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MATN Stock News HeadlinesNemus Bioscience (OTCMKTS:NMUS) vs. Mateon Therapeutics (OTCMKTS:MATN) Head to Head ReviewMay 11, 2026 | americanbankingnews.comViking Therapeutics Inc.February 27, 2024 | wsj.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free. | Reagan Gold Group (Ad)Sorrento Therapeutics Stock (OTC:SRNEQ), Quotes and News SummaryFebruary 25, 2023 | benzinga.comSee More Headlines MATN Stock Analysis - Frequently Asked Questions How have MATN shares performed this year? Mateon Therapeutics' stock was trading at $0.0784 at the beginning of 2026. Since then, MATN stock has decreased by 28.6% and is now trading at $0.0560. How were Mateon Therapeutics' earnings last quarter? Mateon Therapeutics, Inc. (OTCMKTS:MATN) posted its earnings results on Wednesday, May, 15th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, hitting the consensus estimate of ($0.02). How do I buy shares of Mateon Therapeutics? Shares of MATN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Mateon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mateon Therapeutics investors own include Amarin (AMRN), Cyclacel Pharmaceuticals (CYCC), Catalyst Pharmaceuticals (CPRX), Oramed Pharmaceuticals (ORMP), Exelixis (EXEL), BioLineRx (BLRX). Company Calendar Last Earnings5/15/2019Today5/17/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:MATN Previous SymbolNASDAQ:MATN CIK908259 Webwww.mateon.com Phone650-635-7000FaxN/AEmployees13Year Founded1996Profitability EPS (Trailing Twelve Months)($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$6.64 million Net MarginsN/A Pretax MarginN/A Return on Equity-64.66% Return on Assets-42.92% Debt Debt-to-Equity RatioN/A Current Ratio0.17 Quick Ratio0.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book0.28Miscellaneous Outstanding Shares90,240,000Free FloatN/AMarket Cap$5.05 million OptionableNot Optionable Beta1.33 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:MATN) was last updated on 5/18/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredThe filing was one thing. June 1 is another.The SpaceX filing got attention - but according to macroeconomic strategist Dr. Mark Skousen of The Oxford Clu...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mateon Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mateon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
